Cardiometabolic Effects of Dapagliflozin in Heart Failure With Reduced or Mildly Reduced Ejection Fraction

NCT ID: NCT05420285

Last Updated: 2022-12-09

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-06-26
• Study Completion Date: 2024-05-31

Brief Summary

Gliflozins have demonstrated a beneficial effect in terms of incident heart failure and related events in patients with or without diabetes. The clinical trial ICARD is an exploratory study that aims to evaluate the cardiometabolic mechanistic effects on the myocardium of dapagliflozin in heart failure with reduced ejection fraction. Deep phenotyping of cardiac and vascular function will be performed using MRI. Myocardial tissue characterization will be based on MRI and FDG-PET for glucose metabolism assessment. Liver steatosis and fibrosis will simultaneously be assessed.

Detailed Description

Open-label, non-controlled clinical trial (Jardé 1) to assess the cardiovascular and metabolic effects of once-daily dapagliflozin 10 mg during 6 months in patients with heart failure and reduced ejection fraction.

Eligibility of patients addressed to the Department of Cardiology (Prof R. Isnard, Pitié-Salpêtrière Hospital, Paris, France) will be investigated at V0: inclusion and exclusion criteria will be checked and informed consent will be signed.

Up to twenty one days after V0, patients will come to the VMRI visit (VMRI) for the cardiac and liver gadolinium-injected MRI and AGE Reader (VRMI) and to the baseline visit (V1). Pregnancy will be ruled out in women of childbearing potential with blood beta-HCG. A blood test (including metabolomics and lipidomics) and FDG-PET MRI including Glucose Tolerance Test (GTT) will be performed. Dapagliflozin 10 mg once daily during six months will be prescribed.

Fifteen to twenty-one days after treatment initiation, a safety visit (V2) will take place in order to verify the tolerance.

A pre-final visit (V3) will be organized after a total of 23 weeks (± 1 week) of treatment. Pregnancy will be ruled out in women of childbearing potential with blood beta-HCG. A blood test (including metabolomics and lipidomics), ECG, trans-thoracic echocardiography (TTE), cardiac and liver MRI and AGE Reader will be performed.

After 24 weeks of treatment (6-month treatment), patients will come to the end of study visit (V4), to undergo the final FDG-PET MRI including Glucose Tolerance Test (GTT).

Conditions

Heart Failure; Reduced Ejection Fraction

Keywords

heart failure; HFrEF; myocardial function; fibrosis; metabolism

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Dapagliflozin

Dapagliflozin is taken orally, once daily at the dosage of 10 mg during 6 months.

Group Type: EXPERIMENTAL

Dapagliflozin

Intervention Type: DRUG

Dapagliflozin (Forxiga) is a very potent selective and reversible inhibitor of SGLT2.

Interventions

Dapagliflozin

Dapagliflozin (Forxiga) is a very potent selective and reversible inhibitor of SGLT2.

Intervention Type: DRUG

Other Intervention Names

Forxiga

Eligibility Criteria

Inclusion Criteria

• Age ≥ 18 years
• NYHA functional class II-IV.
• Previous hospitalization for heart failure anytime or NT-proBNP >125 pg/ml in the previous 12 months
• Left ventricular ejection fraction ≤ 50% measured at least 1 time in transthoracic echocardiography in the last 12 months
• Treated by optimal medical therapy (ACE-I or angiotensin receptor blocker or sacubitril-valsartan, and betablockers, and mineralocorticoid receptor antagonist and furosemide) unless such use was contraindicated or previously associated with side-effects leading to drug discontinuation. No change in drugs dosages in the last month.
• Able to give written informed consent
• If female of childbearing potential, have a negative serum pregnancy test
• Use of a validated method of birth control until the end of the study (men and women)
• Affiliation to a social security regime

Exclusion Criteria

• Hypersensitivity to dapagliflozin or to any of the excipients
• Current treatment with gliflozine
• Cardiac rhythm disorder including atrial fibrillation > 100 bpm
• Significant valvular heart disease including mitral or aortic regurgitation > II/IV
• Hospitalisation for heart failure or unplanned visit for worsening heart failure in the last month
• Recent (last 3 months) or planned coronary revascularization
• Acute coronary syndrome, stroke, or transient ischemic attack in the last 3 months
• Body mass-index > 40 kg/m2
• Uncontrolled type 2 diabetes (Hb1AC > 9%) or type 1 diabetes
• Genetic diabetes (Maturity Onset Diabetes of the Young, MODY)
• Current treatment for cancer, cardiotoxic cancer treatment in the last year
• Treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones in the last 6 weeks
• Active infectious diseases
• Hypovolemia or dehydration, severe hypokalaemia, or severe hyponatremia
• Contraindication to MRI or to contrast agents used
• Estimated glomerular filtration rate (eGFR) < 30 ml per minute per 1.73 m2 of body-surface area (according to the Modification of Diet in Renal Disease criteria)
• Patient on AME (state medical aid)
• Pregnant or breast-feeding female
• Current participation in another interventional study or being in the exclusion period at the end of a previous study
• Patient protected by law (guardianship, tutelage measure, deprived of liberty)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alban REDHEUIL, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique - Hôpitaux de Paris

Locations

Pitié-Salpêtrière Hospital

Paris, , France

Site Status: RECRUITING

Countries

France

Central Contacts

Alban REDHEUIL, MD PhD

Role: CONTACT

Phone: +33(0)1.42.16.55.45

Email: alban.redheuil@aphp.fr

Fabrizio ANDREELLI, MD PhD

Role: CONTACT

Phone: 33(0)1.42.17.80.59

Email: fabrizio.andreelli@aphp.fr

Facility Contacts

Alban REDHEUIL, MD PhD

Role: primary

Other Identifiers

2021-000481-14

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

APHP210166

Identifier Type: -

Identifier Source: org_study_id